Here are five insights:
1. Amgen is leading the $25 million financing round.
2. The startup, Fortuna Fix, is striving to develop novel techniques for re-growing damaged neural tissue.
3. Fortuna Fix has re-engineered multipotent stem cells into neural stem cells.
4. The idea is providers can inject these cells into patients multiple times, creating a treatment processes for tissue regeneration.
5. This investment reflects Amgen’s first in the regenerative medicine space.
More articles on biologics:
Global spine biologics market to expand at 2% CAGR through 2020: 5 insights
Stanford creates gel for neural stem cell regeneration: 6 things to know
Xtant Medical, curasan enter distribution agreement: 5 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
